Overview

* Enanta fiscal Q4 revenue missed analyst expectations

* Net loss for fiscal Q4 narrows year-over-year, indicating improved financial performance

* Company maintains "strong" cash position, bolstered by October 2025 public offering

Outlook

* Enanta plans to file IND for EPS-3903 in the second half of 2026

* Company expects cash and revenue to fund operations into fiscal 2029

* Enanta to submit IND for EDP-978 in Q1 2026

Result Drivers

* ABBVIE SALES - Increase in quarterly revenue attributed to higher sales of AbbVie's MAVYRET®/MAVIRET®

* REDUCED R&D EXPENSES- Research and development expenses were $23.8 million for the three months ended September 30, 2025, compared to $30.8 million for the three months ended September 30, 2024

*

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q4 Miss $15.13 $15.96

Revenue mln mln (6

Analysts

)

Q4 Net -$18.7

Income mln

Q4 $33.51

Operatin mln

g

Expenses

Q4 -$18.39

Operatin mln

g Income

Q4 -$18.67

Pretax mln

Profit

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for Enanta Pharmaceuticals Inc ( ENTA ) is $20.00, about 39.7% above its November 14 closing price of $12.06

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)